Document Detail


Preclinical comparison of mTHPC and verteporfin for intracavitary photodynamic therapy of malignant pleural mesothelioma.
MedLine Citation:
PMID:  16785733     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Efficacy and tumour selectivity of photodynamic therapy with two clinically approved sensitizers (mTHPC, verteporfin) were assessed for focal intracavitary photodynamic therapy (PDT) in rodents with malignant pleural mesothelioma (MPM) at recommended drug-light conditions and at escalating sensitizer dosages. MPM tumours were generated in 15 Fischer rats by subpleural mediastinal tumour cell injection followed after 5 days by intracavitary PDT with light delivery monitored by in situ dosimetry. Animals were intravenously sensitized either with mTHPC (0.1 mg/kg, n = 3; 0.2 mg/kg, n = 3) followed after 4 days by illumination with 20 J/cm(2) at 652 nm, or with verteporfin (0.6 mg/kg, n = 3; 1.2 mg/kg, n = 3) followed after 20 min by illumination with 100 J/cm(2) at 689 nm. Three untreated tumour-bearing animals served as controls. Histological evaluation of the treated tumour and of adjacent normal organs was performed 10 days after tumour implantation. The extent of PDT-induced tumour necrosis was compared to the non-necrosed area and expressed in percentage. A locally invasive growing MPM tumour (3.1 +/- 1 mm diameter) without spontaneous necrosis diameter was found in all animals. For both sensitizers, focal intracavitary PDT was well tolerated at drug-light conditions recommended for clinical applications. Mediastinal organs were spared for both sensitizers but verteporfin resulted in a higher extent of tumour necrosis (80%) than mTHPC (50%). Drug dose escalation revealed a higher extent of PDT-related tumour necrosis for both sensitizers (mTHPC 55%, verteporfin 88%), however, verteporfin-PDT was associated with a higher toxicity than mTHPC-PDT.
Authors:
Isabelle Opitz; Thorsten Krueger; Youmin Pan; Hans-Jorg Altermatt; Georges Wagnières; Hans-Beat Ris
Related Documents :
20836753 - Preclinical disposition and pharmacokinetics-pharmacodynamic modeling of biomarker resp...
22755813 - Su-d-brcd-05: evaluation of new exit detector based transit dosimetry software for tomo...
15947923 - Dermal absorption of permethrin following topical administration.
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2006-06-19
Journal Detail:
Title:  European surgical research. Europäische chirurgische Forschung. Recherches chirurgicales européennes     Volume:  38     ISSN:  0014-312X     ISO Abbreviation:  Eur Surg Res     Publication Date:  2006  
Date Detail:
Created Date:  2006-06-20     Completed Date:  2006-09-13     Revised Date:  2006-11-30    
Medline Journal Info:
Nlm Unique ID:  0174752     Medline TA:  Eur Surg Res     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  333-9     Citation Subset:  IM    
Affiliation:
Thoracic Surgery Service, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cell Line, Tumor
Disease Models, Animal
Mesoporphyrins / pharmacology*,  toxicity
Mesothelioma / drug therapy*,  pathology
Mice
Necrosis
Photochemotherapy*
Photosensitizing Agents / pharmacology*,  toxicity
Pleural Neoplasms / drug therapy*,  pathology
Porphyrins / pharmacology*,  toxicity
Rats
Rats, Inbred F344
Survival Rate
Chemical
Reg. No./Substance:
0/Mesoporphyrins; 0/Photosensitizing Agents; 0/Porphyrins; 0/temoporfin; 129497-78-5/verteporfin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intestinal duplications--experience in 6 cases.
Next Document:  Implantation of the human embryo: research lines and models. From the implantation research network ...